The Diabetes Prevention Program (DPP), funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and conducted at 25 centers nationwide, was a landmark trial to show that lifestyle changes or metformin can effectively delay diabetes in a diverse population of overweight or obese American adults at high risk of diabetes in the short term and long term compared to placebo.
The public health implications of T2D and the high-risk state of Pre-DM cannot be over-stated, with estimated prevalence of ~25 and ~79 million, respectively. Type 2 diabetes is the main cause of kidney failure, limb amputations, and new onset blindness in adults and a major cause of heart disease and stroke. Type 2 diabetes, which accounts for up to 95 percent of all diabetes cases, becomes more common with increasing age. The prevalence of diagnosed diabetes has more than doubled in the last 30 years, due in large part to the upsurge in obesity.
The goal of DPPOS was to study whether the relatively short-term benefits of delaying diabetes demonstrated in the DPP would translate into long-lasting impact. DPPOS had the following major goals, to determine the effect of DPP interventions on: 1) durability of T2D development; 2) early microvascular disease; and 3) atherosclerosis and CVD risk factors.
For protocol and more details, see About DPP and About DPPOS. For clinical trials.gov information, go to the DPP and DPPOS listings. For study questions, please contact the Coordinating Center here. Click here to read questions and answers about the DPP/DPPOS.
We thank our participants whose commitment and dedication continue to expand our knowledge of diabetes prevention! Your contributions carry on!
The DPPOS Research Group has published over 100 manuscripts with funding support and scientific input from:
NIDDK • NHLBI • NIA • NEI • NCI • ORWH • NICHD • CDC • NIMHD • IHS • ADA
"If you're tipping over into diabetes, you're better off with diet and exercise than you are with medication." -Francis S. Collins, 2010
The biguanide class of antidiabetic drugs, which includes metformin, originates from the French lilac or goat's rue (Galega officinalis), a plant used in folk medicine for several centuries.
May 30, 2017
The DPP Research Group will present four posters and one oral presentation at the ADA's 77th Scientific Sessions in San Diego this year June 9-13, 2017. Click here for the schedule of DPP/DPPOS Presentations.
May 26, 2017
Congratulations to our current and past DPPOS investigators for their recent ADA achievements:
- Dana Dabelea: Kelly West Award
- Brenda Montgomery: Deliver the President, Health Care & Education Address
All will be honored at the ADA's 77th Scientific Sessions in San Diego this year. Congratulations!
February 3, 2017
Dr. Sherita Hill Golden, the DPPOS Principal Investigator at the Johns Hopkins clinical site, has been named the co-recipient of the 2017 Walter Reed Distinguished Achievement Award. Click here to read more.
August 1, 2016
Dr. Abbas Kitabchi, a pioneer investigator on pivotal studies in the field of diabetes, including the landmark DCCT/EDIC and DPP/DPPOS studies, passed away on July 18, 2016. Click here to read more.
Program Staff Only: To access the research group website, please click here.
DPPOS Coordinating Center